title: PIK3CD promoted proliferation in diffuse large B cell lymphoma through upregulation of c-myc.
abstract: Despite PIK3CD has been extensively reported in cancers, however, little evidence has been available regarding its role in the setting of diffuse large B cell lymphoma (DLBCL). In the present study, to investigate the role of PIK3CD in DLBCL, relevant experiments were carried out on both in vivo clinical tissue level and in vitro cell line level. Prognostic and clinicopathological significance were analyzed after immunohistochemical assay of PIK3CD expression on DLBCL tissue microarray. MTT assay and flow cytometry were employed to evaluate the proliferative variation, cell cycle, and apoptosis. Athymic nude mice xenografted with DLBCL cell line were employed to confirm the role of PIK3CD. It was found that there was a significant difference between expression of PIK3CD and international prognosis index (IPI), performance state (PS), and inferior overall prognosis. Furthermore, PIK3CD can promote proliferation and prevent apoptosis in DLBCL cells in vitro through upregulation of c-myc and p-AKT and in contrast downregulation of p21 and p27. In nude mice model, knock-down of PIK3CD was shown to be able to suppress the proliferation of DLBCL but not significantly compared with control group. Taken together, our study showed that PIK3CD can promote proliferation of DLBCL cells both in vitro and in vivo, suggesting that PIK3CD could be druggable in the therapy of DLBCL.
authors.affiliation: Department of Pathology, Fudan University Shanghai Cancer Center, 270 Dong'an Road, Shanghai, 200032, China. cwl860@163.com.|Department of Pathology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, 830011, Xinjiang, China. cwl860@163.com.
authors.forename: Wenli
authors.initials: W
authors.lastname: Cui
authors.affiliation: Clinical Medical Research Institute, First Affiliated Hospital of Xinjiang Medical University, Xinjiang Uygur Autonomous Region, Urumqi, 830011, Xinjiang, China.|State Key Lab Incubation Base of Xinjiang Major Diseases Research, First Affiliated Hospital of Xinjiang Medical University, Xinjiang Uygur Autonomous Region, Urumqi, 830011, China.
authors.forename: Shutao
authors.initials: S
authors.lastname: Zheng
authors.affiliation: Department of Pathology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, 830011, Xinjiang, China.
authors.forename: Xinxia
authors.initials: X
authors.lastname: Li
authors.affiliation: Department of Pathology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, 830011, Xinjiang, China.
authors.forename: Yuqing
authors.initials: Y
authors.lastname: Ma
authors.affiliation: Department of Pathology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, 830011, Xinjiang, China.
authors.forename: Wei
authors.initials: W
authors.lastname: Sang
authors.affiliation: Department of Pathology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, 830011, Xinjiang, China.
authors.forename: Ming
authors.initials: M
authors.lastname: Liu
authors.affiliation: Department of Pathology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, 830011, Xinjiang, China.
authors.forename: Wei
authors.initials: W
authors.lastname: Zhang
authors.affiliation: Department of Pathology, Fudan University Shanghai Cancer Center, 270 Dong'an Road, Shanghai, 200032, China. xyzhou100@yahoo.com.
authors.forename: Xiaoyan
authors.initials: X
authors.lastname: Zhou
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000235:genetics; D015153:Blotting, Western; D002453:Cell Cycle / Q000235:genetics; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D058534:Class I Phosphatidylinositol 3-Kinases / Q000096:biosynthesis* / Q000235:genetics; D050759:Cyclin-Dependent Kinase Inhibitor p21 / Q000378:metabolism; D050760:Cyclin-Dependent Kinase Inhibitor p27 / Q000378:metabolism; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D016403:Lymphoma, Large B-Cell, Diffuse / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D016688:Mice, Inbred NOD; D008819:Mice, Nude; D016513:Mice, SCID; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism; D016271:Proto-Oncogene Proteins c-myc / Q000378:metabolism*; D034622:RNA Interference; D014183:Transplantation, Heterologous; D015854:Up-Regulation
chemical_list: C493956:CDKN1A protein, human; D050759:Cyclin-Dependent Kinase Inhibitor p21; D016271:Proto-Oncogene Proteins c-myc; D050760:Cyclin-Dependent Kinase Inhibitor p27; D058534:Class I Phosphatidylinositol 3-Kinases; C486018:PIK3CD protein, human; D051057:Proto-Oncogene Proteins c-akt
keywords: Diffuse large B cell lymphoma (DLBCL); PIK3CD; Prognosis; Proliferation